October 2014, Vol 3, No 7
Personalized Medicine in Oncology Proudly Presents the Third Annual World Cutaneous Malignancies Congress and PMO Live: A Global Biomarkers Consortium InitiativeLetter to Our Readers
Personalized Medicine in Oncology (PMO) is pleased to present the third annual meetings of both the World Cutaneous Malignancies Congress (WCMC) and PMO Live: A Global Biomarkers Consortium Initiative. These will take place consecutively in San Francisco, California, October 29 – November 1, 2014.
As Coeditor in Chief of PMO, Conference Chair of the WCMC, and faculty for PMO Live, it is my pleasure to offer information to you about the purpose and benefits of these meetings.
The WCMC was created in light of the astonishing recent advances made in the field of cutaneous malignancies. As an oncologist who treats melanoma, it wasn’t long ago that we did not have many therapeutic options for patients with melanoma, and outcomes were poor. Currently, there is tremendous progress being made and, consequently, much to keep up on. The agenda for the WCMC covers recent advances and includes debates and discussions on controversial topics, extensive panel discussions with case scenarios, multidisciplinary tumor boards, Q&A sessions, as well as translational workshops focusing on future strategies in development for the treatment of cutaneous T-cell lymphoma, basal cell carcinoma, and malignant melanoma. This is the premiere meeting focusing on the optimal treatment of patients with cutaneous malignancies.
Immediately following the WCMC, we are proud to present PMO Live: A Global Biomarkers Consortium Initiative (formally known as the Global Biomarkers Consortium). This meeting is of paramount importance because PMO Live is the educational forum for the genomic era in oncology, addressing precision medicine techniques, biomarkers, pathways, and clinical application across all cancer types. However, it’s not only about the science and clinical application; part of the mission of PMO Live is to raise awareness among general practitioners, regulatory authorities, and payers to address the myriad of issues brought up by the coming paradigm shift in cancer treatments.
In this issue of PMO, you will find abstracts from each of these meetings. Our December issue will feature summaries, reviews, and case studies from each meeting. For more information, please visit www.cutaneousmalignancies.com and www.pmo-live.com.
Sanjiv S. Agarwala, MD
Coeditor in Chief
Personalized Medicine in Oncology
One of the areas of personalized medicine that has signaled a new era is the development of genetic signatures that can be used to select therapy that is likely to be effective in separate disease sites: for example, Oncotype DX for breast and colon cancer and MammaPrint for breast cancer. [ Read More ]
Prostate cancer is the most common noncutaneous cancer in men and the second most common cause of cancer-related death.1 Normal prostate cells and prostate cancer cells require the presence of androgen for growth and survival. In advanced prostate cancer, androgen deprivation therapy (ADT), medically or surgically, has been the mainstay. [ Read More ]